Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
VAXELIS (Maxx Pharma Pty Ltd)
Product name
VAXELIS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
158 (255 working days)
Active ingredients
DTPa5-HB-IPV-Hib
Registration type
NCE/NBE
Indication
VAXELIS (DTPa5-HB-IPV-Hib) (suspension for injection) is indicated for primary and booster vaccination in infants and toddlers from the age of 6 weeks, against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib).
The use of VAXELIS should be in accordance with official recommendations.